Circulating Tumour DNA (ctDNA) as a Predictor of Clinical Outcome in Non-Small Cell Lung Cancer Undergoing Targeted Therapies: A Systematic Review and Meta-Analysis.

Subgroup Analysis Age stratification: Overall the age did not impact the outcome; however older patients aged > 60 years with positive ctDNA at baseline had a slight trend towards poor PFS compared to ctDNA negative patients [pHR = 1.62; 95%CI: 0.72–2.52, p < 0.001; I 2 = 71.28%], while younger patients (age ≤60 years) showed no difference ([pHR = 1.11; 95%CI: 0.39–1.84, p < 0.001; I 2 = 98.26%]; Supplementary Figure S3a ).

also in 857 other papers

The pooled HR showed a trend towards better OS only for good-quality studies ( Supplementary Figure S8 ) in the sensitivity analysis, while there was no association between poor- and fair-quality studies.

also in 11,799 other papers